BAKER BROS. ADVISORS LP — 13F Holdings & Portfolio

CIK 1263508 · latest 13F-HR filed 2026-08-14

BAKER BROS. ADVISORS LP manages $19.96B in 13F-reported U.S. long-equity assets across 84 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are INCY (17.48%), ONC (12.57%), RVMD (10.74%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 8 new positions and exited 8; 48 existing positions rose in reported value and 17 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$19.96B

Long-equity book

Holdings
84

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+8 / −8 / ↑48 / ↓17

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 72.8%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 27, 2026.

Assets Under Management
$28.15B
Discretionary
$28.15B
Employees
60
Accounts
2
Address
860 WASHINGTON STREET, 3RD FLOOR
NEW YORK, NY 10014
Phone
(212) 339-5600
Name Title / Status Ownership Type
BAKER BROS. ADVISORS (GP), LLC ControlGENERAL PARTNER
since Jan 2000
Less than 5%Domestic Entity
BAKER, FELIX, JAMES ControlLIMITED PARTNER
since Jan 2000
25–50%Individual
BAKER, JULIAN, CHARLES ControlLIMITED PARTNER
since Jan 2000
25–50%Individual
LESSING, SCOTT, LAWRENCE ControlPRESIDENT, CHIEF COMPLIANCE OFFICER
since Feb 2011
Less than 5%Individual
TOOHEY, ALEXANDRA, ANN ControlCHIEF FINANCIAL OFFICER
since Jan 2014
Less than 5%Individual
BAKER, FELIX, JAMES Control
Indirect owner via BAKER BROS. ADVISORS (GP), LLC
MANAGING MEMBER
since Jan 2000
50–75%Individual
BAKER, JULIAN, CHARLES Control
Indirect owner via BAKER BROS. ADVISORS (GP), LLC
MANAGING MEMBER
since Jan 2000
50–75%Individual
Ownership & leadership changes · 4 filings with changes since Feb 13, 2012

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 18, 2019 filing
  • ChangedBAKER, FELIX, JAMES · title CO-MANAGING MEMBER → LIMITED PARTNER
  • ChangedBAKER, FELIX, JAMES · indirect via BAKER BROS. ADVISORS (GP), LLC: title MEMBER → MANAGING MEMBER
  • ChangedBAKER, JULIAN, CHARLES · title CO-MANAGING MEMBER → LIMITED PARTNER
  • ChangedBAKER, JULIAN, CHARLES · indirect via BAKER BROS. ADVISORS (GP), LLC: title MEMBER → MANAGING MEMBER
Mar 29, 2018 filing
  • ChangedBAKER BROS. ADVISORS (GP), LLC · now a control person
Mar 28, 2017 filing
  • AddedBAKER BROS. ADVISORS (GP), LLC · GENERAL PARTNER · Less than 5%
  • AddedBAKER, FELIX, JAMES · MEMBER · 50–75% · indirect via BAKER BROS. ADVISORS (GP), LLC · control person
  • AddedBAKER, JULIAN, CHARLES · MEMBER · 50–75% · indirect via BAKER BROS. ADVISORS (GP), LLC · control person
  • ChangedBAKER, FELIX, JAMES · ownership 50–75% → 25–50%
  • ChangedBAKER, JULIAN, CHARLES · ownership 50–75% → 25–50%
Mar 31, 2014 filing
  • No longer listedKIRBY, LEO, EDWARD · CHIEF FINANCIAL OFFICER · Less than 5% · listed since Jan 2002
  • AddedTOOHEY, ALEXANDRA, ANN · CHIEF FINANCIAL OFFICER · Less than 5% · control person
Feb 13, 2012 filing (earliest on record)
  • ListedBAKER, FELIX, JAMES · CO-MANAGING MEMBER · 50–75% · control person
  • ListedBAKER, JULIAN, CHARLES · CO-MANAGING MEMBER · 50–75% · control person
  • ListedKIRBY, LEO, EDWARD · CHIEF FINANCIAL OFFICER · Less than 5%
  • ListedLESSING, SCOTT, LAWRENCE · PRESIDENT, CHIEF COMPLIANCE OFFICER · Less than 5% · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

BAKER BROS. ADVISORS LP Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 Incyte Corporation INCY 45337C102 $3.49B 17.48% 30,762,330 SH
2 BeOne Medicines Ltd. ONC 07725L102 $2.51B 12.57% 8,801,567 SH
3 Revolution Medicines, Inc. RVMD 76155X100 $2.14B 10.74% 11,443,357 SH
4 Madrigal Pharmaceuticals, Inc. MDGL 558868105 $1.15B 5.77% 2,143,131 SH
5 ACADIA Pharmaceuticals Inc. ACAD 004225108 $1.09B 5.44% 42,912,904 SH
6 Kymera Therapeutics, Inc. KYMR 501575104 $992.7M 4.97% 8,657,242 SH
7 Insmed Incorporated INSM 457669307 $937.8M 4.70% 8,796,111 SH
8 Celcuity Inc. CELC 15102K100 $828.2M 4.15% 7,915,792 SH
9 Kodiak Sciences Inc. KOD 50015M109 $776.1M 3.89% 19,919,186 SH
10 Rhythm Pharmaceuticals, Inc. RYTM 76243J105 $622.3M 3.12% 5,604,483 SH
11 Praxis Precision Medicines, Inc. PRAX 74006W207 $587.0M 2.94% 1,753,198 SH
12 Alkermes plc ALKS G01767105 $524.6M 2.63% 10,012,267 SH
13 Summit Therapeutics Inc. SMMT 86627T108 $477.7M 2.39% 32,786,348 SH
14 GRAIL, Inc. GRAL 384747101 $275.0M 1.38% 4,028,614 SH
15 AbCellera Biologics Inc. ABCL 00288U106 $259.1M 1.30% 33,012,138 SH
16 Immunovant, Inc. IMVT 45258J102 $209.4M 1.05% 5,435,220 SH
17 IDEAYA Biosciences, Inc. IDYA 45166A102 $186.7M 0.94% 5,010,030 SH
18 Kiniksa Pharmaceuticals International, plc KNSA G52694109 $181.3M 0.91% 2,834,643 SH
19 Roivant Sciences Ltd. ROIV G76279101 $166.9M 0.84% 4,716,831 SH
20 Arrowhead Pharmaceuticals, Inc. ARWR 04280A100 $162.4M 0.81% 1,992,783 SH
21 Ionis Pharmaceuticals, Inc. IONS 462222100 $162.4M 0.81% 2,047,727 SH
22 Edgewise Therapeutics, Inc. EWTX 28036F105 $150.4M 0.75% 3,701,719 SH
23 Replimune Group, Inc. REPL 76029N106 $122.3M 0.61% 11,045,336 SH
24 Nurix Therapeutics, Inc. NRIX 67080M103 $113.0M 0.57% 4,658,556 SH
25 Stoke Therapeutics, Inc. STOK 86150R107 $109.2M 0.55% 3,336,697 SH
26 Monte Rosa Therapeutics, Inc. GLUE 61225M102 $105.2M 0.53% 4,345,736 SH
27 Immatics N.V. IMTX N44445109 $96.3M 0.48% 9,508,565 SH
28 Denali Therapeutics Inc. DNLI 24823R105 $96.0M 0.48% 3,734,336 SH
29 Crinetics Pharmaceuticals, Inc. CRNX 22663K107 $88.0M 0.44% 2,351,465 SH
30 Dianthus Therapeutics, Inc. DNTH 252828108 $83.1M 0.42% 852,164 SH
31 Structure Therapeutics Inc. GPCR 86366E106 $76.9M 0.39% 1,432,529 SH
32 Celcuity Inc. CELC 15102KAA8 $69.2M 0.35% 30,750,000 PRN
33 Rapport Therapeutics, Inc. RAPP 75383L102 $64.5M 0.32% 1,547,090 SH
34 Alumis Inc. ALMS 022307102 $56.6M 0.28% 2,012,500 SH
35 Prelude Therapeutics Inc. PRLD 74065P101 $54.0M 0.27% 10,123,824 SH
36 Relay Therapeutics, Inc. RLAY 75943R102 $52.9M 0.27% 2,826,783 SH
37 Mirum Pharmaceuticals, Inc. MIRM 604749101 $52.2M 0.26% 445,975 SH
38 Bicycle Therapeutics plc BCYC 088786108 $46.2M 0.23% 10,885,357 SH
39 Enliven Therapeutics, Inc. ELVN 29337E102 $45.9M 0.23% 905,191 SH
40 Celldex Therapeutics, Inc. CLDX 15117B202 $44.0M 0.22% 1,182,611 SH
41 Viridian Therapeutics, Inc. VRDN 92790C104 $43.8M 0.22% 2,383,025 SH
42 Design Therapeutics, Inc. DSGN 25056L103 $38.8M 0.19% 2,678,430 SH
43 Entrada Therapeutics, Inc. TRDA 29384C108 $37.3M 0.19% 5,072,730 SH
44 Faeth Therapeutics, Inc. FTH 81728A207 $32.2M 0.16% 1,286,411 SH
45 Aktis Oncology, Inc. AKTS 01021M104 $32.1M 0.16% 996,351 SH
46 Neurogene Inc. NGNE 64135M105 $31.2M 0.16% 991,691 SH
47 Jade Biosciences, Inc. JBIO 008064206 $27.3M 0.14% 1,230,426 SH
48 Taysha Gene Therapies, Inc. TSHA 877619106 $27.3M 0.14% 4,004,756 SH
49 Arcus Biosciences, Inc. RCUS 03969F109 $26.0M 0.13% 844,816 SH
50 Disc Medicine, Inc. IRON 254604101 $25.6M 0.13% 349,657 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $19.96B 84 0001104659-26-097191
2026-03-31 2026-05-15 $17.42B 84 0001104659-26-062547
2025-12-31 2026-02-17 $17.08B 86 0001104659-26-016374
2025-09-30 2025-11-14 $13.84B 91 0001104659-25-112595
Filer Information
Address
860 WASHINGTON STREET
3RD FLOOR
NEW YORK, NY 10014
Phone
(212) 339-5600
Filing Manager
BAKER BROS. ADVISORS LP
NEW YORK, NY
Signatory
Alexandra Toohey
Chief Financial Officer